Prostate Cancer
Conditions
Interventions
Oxycodone Group:Based on relevant literature on the use of oxycodone for sedation in elderly patients, the initial dose of oxycodone was set at 15 µg/kg. The dose for the next patient was determined u
Grade 2 (involuntary limb movement that interfered with the procedure and required additional anesthetics)
Grade 3 (agitation with complete inability to cooperate, requiring procedure termination and resumption after deepening anesthesia). If a positive response affecting the surgical procedure occurred, t
otherwise, it was decreased by one gradient. The adjacent dose gradient was 1.5 µg/kg. A dose crossover point was recorded when a "positive response converted to a negative response" or vice versa. Th
Sponsors
Union Hospital Affiliated to Fujian Medical University
Eligibility
Sex/Gender
Male
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male patients aged >= 65 years scheduled for prostate biopsy; 2. American Society of Anesthesiologists (ASA) physical status classification ?-?; 3. Body Mass Index (BMI) ranging from 18.5 to 24 kg/m²; 4. Voluntary participation in the study and signing of the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergy to oxycodone, propofol, or other opioid drugs; 2. Presence of severe cardiovascular and cerebrovascular diseases (e.g., unstable angina pectoris, myocardial infarction, severe arrhythmia, acute phase of stroke, etc.); 3. Severe liver or kidney dysfunction (e.g., Child-Pugh class C liver function, creatinine clearance rate < 30 ml/min); 4. Expected difficult airway, obstructive sleep apnea syndrome, myasthenia gravis, or other diseases affecting respiration; 5. Known or suspected gastrointestinal obstruction (e.g., paralytic ileus); 6. History of mental illness, drug abuse, or alcohol abuse; 7. Long-term use of opioid drugs or other medications affecting pain perception; 8. Participation in other clinical studies within 1 month; 9. Patients deemed inappropriate to participate by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ED?? of oliceridine combined with propofol for suppressing body?movement response in elderly patients undergoing prostate biopsy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sedation score at immediate emergence from anesthesia;NRS score at 0.5 h after emergence from anesthesia;Perioperative adverse reactions; | — |
Countries
China
Contacts
Public ContactXiuru Chen
Union Hospital Affiliated to Fujian Medical University
Outcome results
None listed